Navigation Links
Cardiome kündigt Anwesenheit auf dem ESC Congress 2013 in Amsterdam an
Date:8/30/2013

r anderen externen Kostenträgern für Produkte und verwandte Behandlungen; Nebenwirkungen oder unerwartete Verzögerungen im vorklinischen und klinischen Produktentwicklungsprozess; nachteilige Ergebnisse bezüglich der Sicherheit und/oder Wirksamkeit unserer Produkte oder von Produkten; die Entscheidungen, und der Zeitplan von Entscheidungen, die von Gesundheitsbehörden in Bezug auf die Zulassung unserer Technologie und Produkten getroffen werden; der Bedarf nach substanziellen Finanzmitteln für die Ausweitung unserer kommerziellen Aktivitäten; und andere Faktoren, die unsere Performance beeinflussen. Darüber hinaus unterliegt unser Geschäft bestimmten betrieblichen Risiken, welche dazu führen können, dass sich durch die zukunftsbezogenen Aussagen in dieser Veröffentlichung ausgedrückten beziehungsweise implizierten Ergebnisse wesentlich von unseren tatsächlichen Ergebnisse unterscheiden. Zu diesen betrieblichen Risiken gehören: unsere Fähigkeit, qualifiziertes Personal anzuziehen und zu halten; unsere Fähigkeit, vorklinische Studien und die klinische Entwicklung unserer Produkte erfolgreich abzuschließen; Änderungen in unserer Geschäftsstrategie beziehungsweise unserer Entwicklungspläne; Belange im Bereich geistiges Eigentum, unter anderem die Unvorhersehbarkeit oder der Verlust unseres Patentschutzes durch die Infragestellung unserer Patente durch Drittparteien; die Marktakzeptanz unserer Technologie und unserer Produkte; unsere Fähigkeit zur erfolgreichen Herstellung, Vermarktung und dem Verkauf unserer Produkte; der Verfügbarkeit von Kapital zur Finanzierung unserer Aktivitäten; und andere Faktoren, die detailliert in unseren Einreichungen bei der Securities and Exchange Commission dargelegt sind und unter http://www.sec.gov und bei den für den Wertpapierhandel zuständigen A
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CardioMEMS Named as a Finalist for Intel Innovation Award
2. CardioMEMS, Inc. wins 2012 Intel Innovation Award
3. CardioMEMS Vice President - Information Systems, Richard Powers, and Chairman of the Board, John Huntz, Selected as Finalists for Prestigious Awards
4. CardioMEMS CFO, Daniel H. Bauer, Honored with a CFO of the Year Award by the Atlanta Business Chronicle
5. Cardiome anuncia su presencia en el Congreso ESC 2013 en Ámsterdam
6. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
7. Simbionix kündigt Lizenzvertrag für chirurgische Videos an
8. Blue Belt Technologies kündigt Gründung eines wissenschaftlichen Beirats für Hüfteingriffe zur Bestimmung neuer Anwendungsgebiete von NavioPFS bei femoro-acetabulärem Impingement an
9. Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an
10. CryoLife kündigt erste Implantation des HeRO Transplantats in Europa an
11. STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Molecular Profiles Ltd., a subsidiary of ... Maryland -based Xceleron have announced a ... clinical development that will be launched at AAPS in ... This partnership extends Molecular Profiles, new ROADMAP to ... this month. The company also has complementary collaborations in ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today reported ... Total revenue was $2.4 million and $5.5 million for the three ... $2.5 million for the same periods in 2010. Total ... 2011, were $7.6 million and $15.0 million as compared to $6.1 ...
... 2011 CORRECTED -- Bionovo, Inc. (NASDAQ: BNVI ... the three months ended June 30, 2011. ... drug candidate, MF101, or Menerba™, during the past quarter, delivering ... and Chief Executive Officer. "We have completed the tasks which ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 9Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 10Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 11CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 2CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 3CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 4CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 5
(Date:10/30/2014)... TX (PRWEB) October 30, 2014 ... released today its 2014 third quarter infection rates ... Texas boasted infection rates of only two percent ... patient satisfaction scores exceeding 98 percent. , “We ... quarter, which included rising satisfaction scores,” said Robert ...
(Date:10/30/2014)... News) -- Scientists who used stem cells to create ... could provide a new way to learn more about ... team used human pluripotent stem cells -- which can ... to grow the functional miniature stomachs, to study infection ... of ulcers and stomach cancer. The miniature stomachs ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Many U.S. colleges ... even though tanning increases the risk for skin ... young adults, particularly white women, so colleges should ... the researchers said. "Public health efforts are ... awareness of the harms that indoor tanning poses ...
(Date:10/30/2014)... A new vaccine that could help prevent some cases ... U.S. Food and Drug Administration on Wednesday. Trumenba ... 10 and 25 from invasive meningococcal disease caused by ... bacteria can infect the bloodstream (sepsis) and the lining ... a leading cause of bacterial meningitis, and infection can ...
(Date:10/29/2014)... and even non-invasive technologies is increasing in the medical ... out a range of operative procedures using keyhole surgery ... scars as a result. Similar opportunities are now becoming ... – instead of using injections or probes to deliver ... them via a plaster which continuously, gently and painlessly ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... ... ... company that launched the first FDA cleared Fourier/spectral domain OCT in the US, announced its ... , ,“Following our 19% revenue growth in 2009 over 2008, we expected the economy and ...
... Emergency services double ... ... announced ambitious plans to add a second inpatient tower to meet what has become an enormous ... beds, more emergency care and more jobs to the Anschutz Medical Campus and the state., , ...
... ... inspire, motivate and empower members of the healthcare team and the patients and family members ... calling for entries now, with winners announced later this year. , ... Rockville, MD (PRWEB) May 24, 2010 -- Dorland ...
... PLoS ONE, Massachusetts General Hospital (MGH) ... individuals unconsciously distribute their preferences regarding approaching or ... appear to meet the strict criteria used to ... if confirmed in future studies, could potentially be ...
... patients with transformed lymphoma showed "remarkable" response to lenalidomide, ... international study, involving 24 medical centers in the United ... Society of Clinical Oncology ( http://www.asco.org/ ) annual meeting ... of patients with transformed lymphoma treated with lenalidomide responded ...
... triggers the need for a night,s rest may be the ... Brain injuries can disrupt the body,s production of the hormone ... , "We,ve known that people often have problems with sleep ... the exact causes of these problems," study author Shantha Rajaratnam ...
Cached Medicine News:Health News:Optovue Q1 2010 Revenue Up 57% Over Same Quarter 2009 2Health News:,University of Colorado Hospital Moving Forward with $400 Million Expansion, 2Health News:,University of Colorado Hospital Moving Forward with $400 Million Expansion, 3Health News:Dorland Health Announces People Awards Honoring Excellence & Dedication Among Healthcare Professionals - Call For Entries 2Health News:Study finds 'law-like' patterns in human preference behavior 2Health News:Study finds 'law-like' patterns in human preference behavior 3Health News:Study identifies promising treatment for aggressive lymphoma 2Health News:Brain Injuries May Lead to Sleep Woes 2
... Ankle Orthosis enables the clinician to ... ankle joint to control muscle imbalance ... a pair of bilateral turnbuckles, controlling ... Simply adjust the turnbuckle to gradually ...
... Protection,Protects the heel while maintaining the ankle ... contact with a soft, cushioning AliPlast™ foam ... and liner cradles the heel in a ... change position freely in bed from side-lying ...
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Medicine Products: